Influence of the BRAF V600E Mutation on Expression of Vascular Endothelial Growth Factor in Papillary Thyroid Cancer
The Journal of Clinical Endocrinology & Metabolism2006Vol. 91(9), pp. 3667–3670
Citations Over TimeTop 10% of 2006 papers
Young Suk Jo, Shengjin Li, Jung Hun Song, Ki Hyun Kwon, Jun Chul Lee, So Young Rha, Hyo Jin Lee, Ji Young Sul, Gi Ryang Kweon, Heung-Kyu Ro, Jin‐Man Kim, Minho Shong
Abstract
BRAF V600E(+) PTC tended to have larger tumor volumes and higher expression of VEGF. The level of VEGF expression was closely correlated with tumor size, extrathyroidal invasion, and stage. The relatively high levels of VEGF expression may be related to poorer clinical outcomes and recurrences in BRAF V600E(+) PTC.
Related Papers
- → Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013(2017)2,149 cited
- → Lessons from Mouse Models of Thyroid Cancer(2009)52 cited
- → CDK12 promotes papillary thyroid cancer progression through regulating the c-myc/β-catenin pathway(2020)20 cited
- → Analysis of the BRAF V600E mutation in primary cutaneous melanoma(2014)26 cited
- → Modern aspects influencing the management of patients with papillary thyroid cancer(2023)3 cited